18 therapeutic antibody-like immunoconjugates against tissue factor with the potential to treat angiogenesis-dependent as well as macrophage-associated human diseases

19 c-reactive protein as a mediator of complement activation and inflammatory signaling in age-related macular degeneration

20 Optical Coherence Tomography-Based Deep-Learning Models for Classifying Normal and Age-Related Macular Degeneration and Exudative and Non-Exudative Age-Related Macular Degeneration Changes.

21 Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

22 Targeting modifiable risk factors in age-related macular degeneration in optometric practice in Sweden

23 Targeting modifiable risk factors in age-related macular degeneration in optometric practice in Sweden

24 Targeting modifiable risk factors in age-related macular degeneration in optometric practice in Sweden

25 Interactome Mapping Guided by Tissue-Specific Phosphorylation in Age-Related Macular Degeneration.

26 Computer-based detection of age-related macular degeneration and glaucoma using retinal images and clinical data

27 Polarization Variability in Age-related Macular Degeneration.

28 Relationship between HTRA1 polymorphism and genetic susceptibility of wet age-related macular degeneration in Han population

29 Influence of mydriasis on optical coherence tomography angiography imaging in patients with age-related macular degeneration.

30 Artificial intelligence for morphology-based function prediction in neovascular age-related macular degeneration.

31 Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.

32 Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?

33 StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.

34 Near-Infrared Reflectance Imaging for Quantification of Atrophy associated with Age-related Macular Degeneration.

35 Analysis of the Arg345Trp disease-associated allele of the EFEMP1 gene in individuals with early onset drusen or familial age-related macular degeneration.

36 [A differentiated approach to analysis of retinal fluid and assessment of its effect on anti-VEGF therapy of neovascular age-related macular degeneration].

37 Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?

38 Retinal Spectral Domain Optical Coherence Tomography in Early Atrophic Age-Related Macular Degeneration (AMD) and a New Metric for Objective Evaluation of the Efficacy of Ocular Nutrition

39 Effects of Retinal Morphology on Contrast Sensitivity and Reading Ability in Neovascular Age-Related Macular Degeneration

40 Retinal-image quality and contrast-sensitivity function in age-related macular degeneration

41 Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration

42 Simple Estimation of Clinically Relevant Lesion Volumes Using Spectral Domain–Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration

43 Effects of Retinal Morphology on Contrast Sensitivity and Reading Ability in Neovascular Age-Related Macular Degeneration

44 Contrast Sensitivity Evaluation in Eyes Predisposed to Age-Related Macular Degeneration and Presenting Normal Visual Acuity

45 Contrast sensitivity evaluation in eyes predisposed to age-related macular degeneration and presenting normal visual acuity

46 Intravitreal Bevacizumab in Neovascular Age-Related Macular Degeneration as First Choice: a New Italian Ruling

47 cGAS drives noncanonical-inflammasome activation in age-related macular degeneration

48 Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab

49 Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab

50 intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration ranibizumab e bevacizumab intravítreo no tratamento da neovascularização de coróide extrafoveal da degeneração macular relacionada à idade

51 ranibizumab with transpupillary thermotherapy for clinical efficacy in wet age-related macular degeneration

52 avaliação da perimetria macular em pacientes com degeneração macular relacionada à idade por meio do oftalmoscópio de rastreamento a laser evaluation of macular perimetry in patients with age-related macular degeneration using the scanning laser ophthalmoscope

53 clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation

54 association of cfi p.gly119arg gene polymorphism with age-related macular degeneration (amd) disease in the population living in tehran

55 long-lasting effects of anti-vegf/photodynamic combination therapy in the treatment of exudative age-related macular degeneration: a retrospective chart review

56 role of the choroid in age-related macular degeneration: a current review

57 successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye

58 treatment of retinal pigment epithelial detachment secondary to exudative age-related macular degeneration

59 progress and perspectives on the role of rpe cell inflammatory responses in the development of age-related macular degeneration

60 european survey on the opinion and use of micronutrition in age-related macular degeneration: 10 years on from the age-related eye disease study

61 choice of cell source in cell-based therapies for retinal damage due to age-related macular degeneration: a review

62 new approaches in the management of choroidal neovascular membrane in age-related macular degeneration.

63 prognostic factors of early morphological response to treatment with ranibizumab in patients with wet age-related macular degeneration

64 efficacy of vitrectomy and epiretinal membrane peeling in eyes with dry age-related macular degeneration

65 automatic screening and grading of age-related macular degeneration from texture analysis of fundus images

66 long-term visual outcome in wet age-related macular degeneration patients depending on the number of ranibizumab injections

67 blockade of tumor necrosis factor-alpha: a role for adalimumab in neovascular age-related macular degeneration refractory to anti-angiogenesis therapy

68 oxidative stress, hypoxia, and autophagy in the neovascular processes of age-related macular degeneration

69 melatonin in retinal physiology and pathology: the case of age-related macular degeneration

70 preservation of the photoreceptor inner/outer segment junction in dry age-related macular degeneration treated by rheohemapheresis

71 visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population

72 Outcomes in the Treatment of Subretinal Macular Hemorrhage Secondary to Age-Related Macular Degeneration: A Systematic Review.

Keyword Connections

Journals

Research Groups

Bibliographies